Phase 3 Liver Cancer Trial, Recruiting NCT07322848 Sponsor: First Affiliated Hospital, Sun Yat-Sen University Condition: Liver Cancer
Back to Liver Cancer

Phase 3 Liver Cancer Trial, Recruiting

NCT07322848
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with liver cancer (hepatocellular carcinoma) that is beyond certain size limits — either a single tumor larger than 5 cm, or three or more tumors with at least one being 3 cm or larger, all within the liver and without spread to other parts of the body.
  • You have not received any cancer treatment in the 12 months before joining the trial.
  • You have previously had a procedure called TIPS (a shunt placed inside the liver to reduce pressure in blood vessels), done to prevent bleeding from enlarged veins or to treat fluid build-up in the abdomen, and this shunt has been confirmed to be working well at a one-month check-up.
  • Your liver is functioning at a level rated as Child-Pugh class A or B (a medical measure of liver health — confirm with trial site).
  • Doctors estimate you are expected to live for at least 3 more months.
  • Your blood counts and organ function meet certain minimum levels, including healthy enough levels of blood cells, liver enzymes, kidney function, and proteins in your blood (confirm specific values with trial site).

Who may not be able to join:

  • Your liver cancer is spread throughout the liver in a diffuse pattern, cannot be measured on scans, or the tumor takes up more than half of the liver.
  • There is a blood clot caused by the tumor blocking the main or branch portal veins in your liver.
  • You have previously had a liver transplant or received any cancer treatment after your TIPS procedure was placed.
  • You have medical reasons why a procedure called TACE (a type of liver-directed treatment) would not be safe for you.
  • The cancer has spread to your brain.
  • You have a known allergy to contrast dye used in scans.
  • You are pregnant, breastfeeding, or planning to become pregnant within the next 2 years.
  • You have HIV or syphilis.
  • You currently have another type of cancer, or have been treated for a different cancer within the past 5 years.
  • You have serious heart, kidney, or other major organ problems.
  • You have a significant active infection that is more than mildly severe (confirm grading with trial site).
  • You have a mental health condition that may affect your ability to understand and agree to participate in the trial.
  • You have taken part in another drug clinical trial within the 12 months before joining this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 13580414494

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov